Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general financial performance.
Material Changes
There are no material changes to the company's financial position reported in this document. The only change noted is an increase in the notional allocation of Ordinary share ADRs for Dr. K Belmonte within the US Retirement Savings Plan due to a re-valuation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on March 18, 2011.
- Price: The transaction price was $37.34 per ADR.
- Individual Involved: Dr. K Belmonte received an increase of 5 Ordinary share ADRs.
- Context: This was a re-valuation of the cash element within the US Retirement Savings Plan, not a direct market purchase.